The AI Journal·3 min read·hard
Aethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update
✦AI Summary
Aethlon Medical reported its fiscal year 2026 financial results and provided an update on its Australian oncology study. The company has advanced to the third and final dosing cohort for its Hemopurifier technology.
Why it matters
Progress in clinical trials for cancer and viral treatments is a key indicator for biotech investment and medical innovation.
Australian oncology study advances into Cohort 3 as enrollment continues
businesshealth
Political Bias
Center
LeftLean LCenterLean RRight
Confidence: 95%
This is a standard corporate financial and clinical update, written in a neutral, informative tone.
✦
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in